10. Charcot-Marie-Tooth disease Clinical trials / Disease details
Clinical trials : 41 / Drugs : 46 - (DrugBank : 9) / Drug target genes : 11 - Drug target pathways : 15
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05361031 (ClinicalTrials.gov) | September 21, 2020 | 31/3/2022 | The Safety and Tolerability of Engensis (VM202) in Patients With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A) | Single Center, Open Label, Repeat Intramuscular Administration, 270 Days, Phase I/2a Clinical Trial to Evaluate Safety, Tolerability of Investigational Product (Engensis: VM202) With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A) | CMT | Biological: Engensis (VM202) | Helixmith Co., Ltd. | NULL | Completed | 19 Years | 65 Years | All | 12 | Phase 1/Phase 2 | Korea, Republic of |